Tender Details
Beyond this tender, use our platform to source any product, service, or solution.
Get direct quotes or register as a qualified provider.
| Particulars | Details |
|---|---|
| Title |
Ranibizumab Intra Vitreal Injection Pfs Approved For All Indications
1.Wet Age Related Macular Degeneration
2.Diabetic Macular Edema
3.Proliferative Diabetic Retinopathy
4.Retinal Vascular Occlusion
5.Myopic Choroidal Neovascularization
6.Retinopathy Of Prematurity
|
| Description |
For Complete Deion And Other Details, Please Refer To Tender
|
| Organisation | Ministry of Railways | Central Govt. Ministry/Department |
| Tender Id | 106787591 |
|
Reference Number |
82253329B |
| Tender Fee | 0 |
| EMD | 0 |
| Tender Value | - |
| Place | Jaipur |
| Link |
View Original Tender Notice
https://www.ireps.gov.in/ireps/supply/pdfdocs/092025/106787591/viewNitPdf_5086535.pdf |
| Start Date | August 21, 2025 18:53 |
| End Date |
Expired
01/09/2025
Expired 381 days ago |
Tender Support
Get help with filing, GeM registration, documents, or relevant tender alerts.
Ranibizumab intra vitreal injection - vial/pfs 1.wet age related macular degeneration 2.diabetic macular edema 3.proliferative diabetic retinopathy 4.retinal vascular occlusion 5.myopic choroidal neovascularization 6.retinopathy of prematurity
For complete deion and other details, please refer to tender
Read moreRanibizumab intra vitreal injection - vial/pfs 1.wet age related macular degeneration 2.diabetic macular edema 3.proliferative diabetic retinopathy 4.retinal vascular occlusion 5.myopic choroidal neovascularization 6.retinopathy of prematurity
For complete deion and other details, please refer to tender
Read moreInj. ranibizumab (each pfs/ amp/vial contains ranibizumab upto 2.3 mg/ 0.23 ml) {the drug should be dgci approved for diabetic macular oedema, retinal vein occlusion, proliferative diabetic retinopathy, retinopathy of prematurity and myopic choroidal neovascular membrane.}
For complete deion and other details, please refer to tender
Read moreRanibizumab 2.3mg inj approved by cdsco for the following indications- 1) wet amd, 2) diabetic macular edema, 3) retinal vein occlusion, 4) myopic cnvm, 5) proliferative diabetic retinopathy
For complete deion and other details, please refer to tender
Read moreInj. ranibizumabo.23ml, 10mg/ml vial, ra [inj. ranibizumabo.23ml, 10mg/ml vial, ranibizumab biosimilar, the medicine should be approved by dcgi/fda for wet amd, diabetic macular edema, rv0, myopic cnvm ,retinopathy of prematurity and pdr .]
For complete deion and other details, please refer to tender
Read moreRunning contract for inj. ranibizumab (10mg/ml)) (0.23mg/0.23ml) for intravitreal injection vial, the medicine should be approved by dcgi for wet armd, diabetic macular oedema, rvo, myopic cnvm, pdr and rop.
For complete deion and other details, please refer to tender
Read moreRunning contract for inj. ranibizumab (10 mg/ml) (0.23 mg/0.23 ml)for intravitreal injection vial. the medicine should be approved by dcgi for wet armd, diabetic macular oedema, rvo, myopic cnvm, pdr and rop.
For complete deion and other details, please refer to tender
Read moreof your Industry type